Preservative-free 0.01% bimatoprost versus other formulations for glaucoma and OHT: Systematic review and meta-analysis of efficacy and safety
Abstract
PurposeTo demonstrate non-inferiority on efficacy and safety of preservative-free bimatoprost 0.01% versus preserved and higher-concentration bimatoprost formulations for the treatment of glaucoma or ocular hypertension (OHT), using a network meta-analysis (NMA).MethodsA systematic review and Bayesian NMA were conducted according to a pre-registered protocol (PROSPERO: CRD420250650769) and PRISMA-NMA guidelines. Randomised controlled trials comparing monotherapies of bimatoprost (preserved or preservative-free) in adults with glaucoma or OHT were included. The primary endpoint was mean intraocular pressure (IOP) at Week 12. Conjunctival hyperaemia, were descriptively analysed. Risk of bias was assessed using the Cochrane RoB 2 tool.ResultsFour studies were included. The Bayesian NMA demonstrated that preservative-free bimatoprost 0.01% was non-inferior to all other bimatoprost formulations in lowering IOP, with all 95% credible intervals falling within the 1.5 mmHg non-inferiority margin. Sensitivity analyses using a frequentist model confirmed these findings. Safety analysis indicated that preservative-free bimatoprost formulations were associated with lower rates of hyperaemia compared to preserved versions. At Week 12, more patients had no hyperaemia with preservative-free bimatoprost 0.01% (57.3% vs. 43.6%) and fewer showed worsening scores (18.3% vs. 30.4%). Hyperaemia reported as an adverse event was also less frequent with bimatoprost 0.01% than 0.03% (28.6% vs.…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 12 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.